Founded by leading molecular scientists Du Preez van Staden (CEO) and Ross Vermeulen (COO) in response to a chronic supply chain disruptions laid bare during the pandemic, Fluorobiotech is an African biotech company built on a clear conviction: that biotechnologies should be locally manufactured, globally competitive, and widely accessible.

Fluorobiotech has developed the globally patented SelfPrep protein production platform, a fundamentally simplified and scalable approach to recombinant protein and enzyme manufacturing: the complex, mission-critical raw materials that power research institutions, vaccine developers, diagnostic solutions, and biopharmaceutical manufacturers worldwide.

Leveraging strong partnerships across Africa, Europe, and North America, Fluorobiotech is enhancing global and regional biomanufacturing with innovative, cost-effective, and accessible protein production solutions. Their technology increases yields, reduces production time by up to 800%, lowers costs, and lessens import dependence—making high-quality proteins and enzymes more accessible for research, diagnostics, and biopharmaceuticals worldwide. As a result, this strengthens Africa’s ability to meet the World Health Organisation’s goal of the continent producing 60% of its vaccines locally by 2040.

Fluorobiotech’s breakthrough platform technology strengthens Africa’s health security by reducing dependence on fragile global supply chains while enhancing research productivity, lowering costs, and accelerating innovation across Africa’s life sciences ecosystem.

Website: Fluorobiotech